DNL.L Regulatory News (DNL)

Hardman & Co Video Event | Diurnal Group plc

Investor Forum

We are delighted to announce that Diurnal Group plc will be presenting at our next Investor Forum on Thursday 23 September at 5:00pm. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A.

The Forum is being hosted by Hardman & Co and investors can register to attend via this link: https://hardman-co.com/p/49CL-HU2/join-our-webinar

Diurnal Group plc is a European, UK-headquartered, specialty pharma company targeting patient needs in chronic, potentially life-threatening, endocrine (hormonal) diseases. Alkindi has been approved and launched in both the EU and the US, and Efmody has been approved recently by the EU and is being prepared for launch.

This webinar represents a key communication channel for investors to keep up to date with the company's strategy and progress. All investors, whether existing shareholders or not, are invited to watch the presentation and take part in the Q&A session afterwards. There is no charge for attending. Investors are encouraged to submit their questions when registering or during the event. A recording of the webinar will be available on the Hardman & Co website shortly after the event for those cannot attend the live presentation.

Register here: https://hardman-co.com/p/49CL-HU2/join-our-webinar

To be first in the know about Hardman & Co's latest digital events, subscribe to the mailing list here.

Our video events are designed to share the latest sector insights and company investment cases from our corporate clients and our expert team of analysts. Click here to subscribe to the Hardman Talks channel on YouTube.

Hardman & Co | 1 Frederick's Place | London | EC2R 8AE | www.hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.